Literature DB >> 15596735

Strategies for managing the side effects of treatments for multiple sclerosis.

Annette Langer-Gould1, Harold H Moses, T Jock Murray.   

Abstract

Disease-modifying therapies for multiple sclerosis (MS) are a mainstay of treatment. All of these agents are associated with side effects, most of which are easily managed with only minimal additional pharmacotherapy. Appropriate patient education and physician support are critical to achieve the best medical outcome and to maximize patient compliance with long-term therapies for this debilitating condition. Although many side effects subside shortly after initiation of treatment, such as flu-like symptoms with interferon treatment, some side effects are cumulative and can become life-threatening if they are unrecognized (e.g., cardiotoxicity with mitoxantrone). Therefore, physicians must be aware of appropriate laboratory monitoring schedules to prevent serious toxicities and to become familiar with less serious but more common side effects that often threaten patient compliance. Patients should be encouraged to communicate with their physicians so that side effects can be managed promptly. This article describes and provides management strategies for side effects associated with MS treatments.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15596735     DOI: 10.1212/wnl.63.11_suppl_5.s35

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  14 in total

1.  The Combined Effect of Nursing Support and Adverse Event Mitigation on Adherence to Interferon Beta-1b Therapy in Early Multiple Sclerosis: The START Study.

Authors:  Suhayl Dhib-Jalbut; Clyde Markowitz; Payal Patel; Francis Boateng; Mark Rametta
Journal:  Int J MS Care       Date:  2012

2.  Polypharmacy in Multiple Sclerosis: Current Knowledge and Future Directions.

Authors:  Joanie Thelen; Valeriy Zvonarev; Sarah Lam; Crystal Burkhardt; Sharon Lynch; Jared Bruce
Journal:  Mo Med       Date:  2021 May-Jun

3.  Management Strategies for Flu-Like Symptoms and Injection-Site Reactions Associated with Peginterferon Beta-1a: Obtaining Recommendations Using the Delphi Technique.

Authors:  June Halper; Diego Centonze; Scott D Newsome; DeRen Huang; Christopher Robertson; Xiaojun You; Guido Sabatella; Vladimir Evilevitch; Leslie Leahy
Journal:  Int J MS Care       Date:  2016 Jul-Aug

Review 4.  Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis.

Authors:  Adnan M Subei; Daniel Ontaneda
Journal:  CNS Drugs       Date:  2015-09       Impact factor: 5.749

5.  Bowman-Birk inhibitor suppresses autoimmune inflammation and neuronal loss in a mouse model of multiple sclerosis.

Authors:  Tarik Touil; Bogoljub Ciric; Elvira Ventura; Kenneth S Shindler; Bruno Gran; Abdolmohamad Rostami
Journal:  J Neurol Sci       Date:  2008-06-10       Impact factor: 3.181

6.  Improving compliance with interferon-beta therapy in patients with multiple sclerosis.

Authors:  Emilio Portaccio; Maria Pia Amato
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 7.  Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.

Authors:  Jerold Chun; Hans-Peter Hartung
Journal:  Clin Neuropharmacol       Date:  2010 Mar-Apr       Impact factor: 1.592

Review 8.  Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term.

Authors:  Kathleen Costello; Patricia Kennedy; Jo Scanzillo
Journal:  Medscape J Med       Date:  2008-09-30

9.  Classification of time series gene expression in clinical studies via integration of biological network.

Authors:  Liwei Qian; Haoran Zheng; Hong Zhou; Ruibin Qin; Jinlong Li
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

10.  Evaluation of the effects of a new drug candidate (GEMSP) in a chronic EAE model.

Authors:  A Mangas; R Coveñas; D Bodet; M de León; S Duleu; M Geffard
Journal:  Int J Biol Sci       Date:  2008-05-22       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.